Kelda G Schonhoff

Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms

W. Leisenring, S. Pergam, R. Walter, 2022, Leukemia.

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

E. Estey, M. Othus, R. Walter, 2023, Leukemia & lymphoma.

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms

E. Estey, M. Sorror, M. Othus, 2022, Leukemia.

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

W. Leisenring, M. Boeckh, D. Fredricks, 2023, Blood advances.

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

E. Estey, M. Othus, R. Walter, 2023, Leukemia.

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

E. Estey, T. Gooley, R. Walter, 2023, Leukemia & lymphoma.